Background {#s1}
==========

Osteogenesis imperfecta (OI) is a group of inherited connective tissue disorders. It presents as reduced bone content and increased skeletal fragility, thereby increasing the likelihood of bone fractures ([@B1]). The etiology of most patients with autosomal hereditary OI (types I-IV) involves mutations in *COL1A1* (MIM 120150) and *COL1A2* (MIM 120160). These two genes encode the α1 and α2 chains of type I collagen, respectively. Together, two α1 chains and one α2 chain form the triple-helix structure of type I collagen. Heterozygous null mutations in *COL1A1* lead to haploinsufficiency and inadequate proα1 (I) production, thereby leading to type I OI. Type I OI has mild clinical symptoms and presents with an increased likelihood of bone fractures in childhood with or without blue sclera; in adulthood, the likelihood of bone fractures gradually decreases ([@B1]). Missense mutations in *COL1A1* or *COL1A2* usually lead to changes in collagen structure, thereby leading to clinical symptoms of moderate to severe type II-IV OI. Because new pathogenic genes that participate in the post-translational modification of type I collagen are continually being discovered, the number of OI types are also increasing continuously. Thus, studies have recommended reclassifying OI into 5 groups according to their pathogenic mechanism. OI caused by mutations in the *COL1A1* or *COL1A2* genes are classified under group A, namely, the group with defects in collagen synthesis, structure, or processing ([@B1]). Although many cases about OI are available in the literature, co-occurrence of OI with pituitary stalk interruption syndrome (PSIS) has never been reported.

Pituitary stalk interruption syndrome refers to a congenital abnormality of the anatomical structure of the pituitary. It has a typical presentation on magnetic resonance imaging, including a reduced or absent anterior pituitary, interruption, or loss of the pituitary stalk, and displacement of the posterior pituitary ([@B2]). Further, it leads to isolated or combined pituitary hormone deficiencies ([@B3]). Currently, its pathologic mechanism is still unknown. Pituitary stalk interruption syndrome is believed to be associated with hereditary and environmental factors, particularly perinatal events ([@B3]).

Here we report a family with OI that was caused by combined heterozygous mutations in both *COL1A1* and *COL1A2* genes. The proband showed co-occurrence of PSIS, whereas his older twin did not, suggesting that the proband either has a non-identified mutation or an epigenetic change related to environmental factors such as a perinatal event.

Case Presentation {#s2}
=================

A 19-year-old male patient who presented with absent secondary sexual characteristics and delayed growth was admitted to the First Affiliated Hospital of China Medical University. The abnormalities in the patient were first noticed by his mother when she compared the patient with his monozygotic twin brother. During puberty, the gap in height between the patient and his twin brother was as much as 20 cm. The twins were born after a 37-week uneventful pregnancy. The mother experienced natural and breech delivery during her labor of the twin brother and the patient, respectively. Past medical history included one fracture on his right ulna when he was 2 years old. The patient\'s father was healthy. Both the patient\'s mother and his twin brother had blue sclera, and they both suffered from bone fractures multiple times before adulthood. The patient\'s parents stood at 172 cm (father) and 160 cm (mother). His twin brother was 170 cm tall.

Physical Exam
-------------

The patient showed the following features: height, 158 cm; weight, 53 kg; BMI, 20.70 kg/m^2^; arm span, 153 cm; upper body height, 67 cm; lower body height, 91 cm; triangular face; light blue sclera ([Figure 1C](#F1){ref-type="fig"}); lack of facial hair; lack of Adam\'s apple; lack of underarm hair; lack of thyroid swelling; carinatum; enlarged breasts; palpable breast nodules; mild tenderness; lack of galactorrhea; lack of pubic hair; a stretched penis length of 4 cm. Both testes were palpable within the scrotum bilaterally.

![Clinical characteristics and gene sequencing results of the patient and his family members. **(A)** Digital radiography of the hands. The phalanges and humeral metaphysis are fused, indicating an age of 14--15 years. **(B)** Pedigree of the patient and gene sequencing results. The father is a heterozygous carrier of the P857T mutation in the *COL1A2* gene. The mother is a heterozygous carrier of the R220X mutation of the *COL1A1* gene. The twin brothers are heterozygous carriers of the above two mutations. **(C)** Light blue sclera of the patient. **(D)** Magnetic resonance imaging of the pituitary of the patient, indicating reduced morphology of the anterior lobe, absence of the pituitary stalk, and displacement of the neurohypophysis to the infundibulum (red arrow).](fendo-10-00193-g0001){#F1}

Work-Up
-------

Testicular ultrasound showed that the right testis had a size of approximately 1.64 × 0.73 × 1.16 cm (0.73 ml), and the left testis had a size of \~1.48 × 0.65 × 1.01 cm (0.51 ml). His sense of smell was also tested formally (T & T olfactometer test), and no olfactory loss or hyposmia was found. Bone mineral density analysis showed decreased bone density in the lumbar vertebrae (Z = −3.1). Digital radiography of both hands indicated his skeletal age to be 14 years ([Figure 1A](#F1){ref-type="fig"}). Magnetic resonance imaging of the pituitary gland showed reduced morphology of the anterior pituitary, absence of a pituitary stalk and ectopic displacement of the posterior lobe to the infundibulum ([Figure 1D](#F1){ref-type="fig"}). These findings together suggested a diagnosis of PSIS. Ophthalmologic and audiologic examinations did not reveal any abnormalities.

Laboratory examinations demonstrated pituitary hypothyroidism, pituitary-adrenal axis dysfunction, hypogonadotropic hypogonadism, slightly increased prolactin level, and presence of insulin resistance with normal blood glucose level ([Table 1](#T1){ref-type="table"}). The basal GH level of the proband was \< 0.5 μg/l and basal IGF-I level was \< 25 ng/ml, suggesting a possibility of growth hormone deficiency, but we didn\'t perform stimulation tests because the patient and his mother refused to take the tests as well as be treated with growth hormone for economic reasons.

###### 

Clinical and laboratory data of the patient at diagnosis and follow up.

                             **At diagnosis**   **Follow up**       **Normal range**                                          
  -------------------------- ------------------ ------------------- -------------------- ----------- -------------- --------- ----
  Weight (Kg)                53                 57                  61                   65          --                       
  Hight (cm)                 158                158                 158.5                158.5       --                       
  Volume of testis (ml)      0.51/0.73          --                  --                   1.47/1.69   --                       
  T (nmol/l)                 \<0.69             4.85                4.54                 4.64        9.08--55.23              
  FT (pmol/l)                2.14               67.25               69.39                65.04       55.05--183.5             
  LH (mIU/l)                 \<0.10             --                  --                   --          0.80--7.60               
  FSH (mIU/l)                0.59               --                  --                   --          0.70--11.10              
  TSH (mIU/l)                5.72               2.37                1.12                 2.39        0.35--4.94               
  fT4 (pmol/l)               7.18               8.61                8.11                 5.28        9.01--19.05              
  fT3 (pmol/l)               3.65               2.1                 4.11                 4.2         2.63--5.7                
  ACTH (pg/ml) (8:00 a.m.)   9.47               9.31                --                   9.15        7.20--63.30              
  COR (nmol/l) (8:00 a.m.)   29.50              112.3               --                   76.5        171--536                 
  GH (μg/l)                  \<0.05             --                  --                   --          0.05--3.00               
  IGF-1 (ng/ml)              \<25               --                  --                   --          115--358                 
  PRL (mIU/l)                547.0              --                  --                   --          53--360                  
                             Fasting            60 min after OGTT   120 min after OGTT   Fasting     Fasting        Fasting   
  PG (mmol/l)                4.33               6.08                5.23                 4.31        4.42           4.52      --
  INS (mIU/l)                21.73              135.40              44.63                --          --             --        --
  CP (pmol/l)                1621.10            7502.00             2579.00              --          --             --        --

*T, testosterone; FT, free testosterone; SHBG, sex-hormone binding globulin; LH, luteinizing hormone; FSH, follicle-stimulating hormone; TSH, thyrotropin-releasing hormone; fT4, free thyroxine; fT3, free triiodothyronine; ACTH, adrenocorticotropic hormone; COR, cortisol; GH, growth hormone; IGF-1, insulin like growth factor-1; PRL, prolactin; PG, plasma glucose; INS, serum insulin; CP, serum C peptide; OGTT, oral glucose tolerance test*.

Genetic Testing
---------------

Blood samples were collected from the patient and his family members (father, mother, and twin brother). Genomic DNA was extracted using a blood extraction kit (Tian Jing Biochemical Technology Beijing, Ltd.). Roche Nimblegen SeqCap EZ Choice XL Library was used for exon trapping (including 4,132 genes). Illumina nextseq500 was used for high-throughput sequencing. Burrows-Wheeler Aligner software (BWA, 0.7.12-r1039) was applied to align the sequencing data to the human genome. ANNOVAR was used to annotate the genetic variants detected (based on the recent version of the dbSNP database, Clinvar, ExAC, and 1000 Genomes Project). Emphasis was laid on the analysis of known genes involved in OI, PSIS, PHD, and HPE according to pathology (listed separately in [Table 2](#T2){ref-type="table"}). The results revealed that the identical twins harbor heterozygous mutations in *COL1A1* (c.658C\>T, p.Arg220Ter) and *COL1A2* (c.2569C\>A, p.Pro857Thr). The mother harbors the same *COL1A1* mutation (p.Arg220Ter) and the father harbors the *COL1A2* (p.Pro857Thr) mutation ([Figure 1B](#F1){ref-type="fig"}). No known pathogenic variants related to PSIS, PHD, or HPE were found in this family. No convincing discordant single nucleotide or indel variants were found in coding or regulatory regions in this phenotypically PSIS-discordant twin.

###### 

List of genes related to bone metabolism, PSIS, PHD, and HPE.

  **Official name**                      **Phenotype**                                                                                                                                                                                                                    **Inheritance**
  -------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -----------------
  **GENES RELATED TO BONE METABOLISM**                                                                                                                                                                                                                                    
  COL1A1                                 Osteogenesis imperfecta, type I(a dominant form with blue sclerae);                                                                                                                                                              AD
  COL1A1, COL1A2                         Osteogenesis imperfecta, type II(a perinatally lethal OI syndrome); Osteogenesis imperfecta, type III(progressively deforming form with normal sclerae); Osteogenesis imperfecta, type IV(a dominant form with normal sclerae)   AD
  IFITM5                                 Osteogenesis imperfecta, type V                                                                                                                                                                                                  AD
  SERPINF1                               Osteogenesis imperfecta, type VI                                                                                                                                                                                                 AR
  CRTAP                                  Osteogenesis imperfecta, type VII                                                                                                                                                                                                AR
  P3H1                                   Osteogenesis imperfecta, type XIII                                                                                                                                                                                               AR
  PPIB                                   Osteogenesis imperfecta, type IX                                                                                                                                                                                                 AR
  SERPINH1                               Osteogenesis imperfecta, type X                                                                                                                                                                                                  AR
  FKBP10                                 Osteogenesis imperfecta, type XI                                                                                                                                                                                                 AR
  SP7                                    Osteogenesis imperfecta, type XII                                                                                                                                                                                                AR
  BMP1                                   Osteogenesis imperfecta, type XIII                                                                                                                                                                                               AR
  TMEM38B                                Osteogenesis imperfecta, type XIV                                                                                                                                                                                                --
  WNT1                                   Osteogenesis imperfecta, type XV                                                                                                                                                                                                 AR
  IDS                                    mucopolysaccharidosis type II (MPS2; Hunter syndrome)                                                                                                                                                                            XLR
  ARSB                                   Mucopolysaccharidosis type VI (Maroteaux-Lamy)                                                                                                                                                                                   AR
  SGSH                                   Mucopolysaccharidisis type IIIA (Sanfilippo A)                                                                                                                                                                                   AR
  NAGLU                                  Mucopolysaccharidosis type IIIB (Sanfilippo B)                                                                                                                                                                                   AR
  HGSNAT                                 Mucopolysaccharidosis type IIIC (Sanfilippo C)                                                                                                                                                                                   AR
  GNS                                    Mucopolysaccharidosis type IIID                                                                                                                                                                                                  AR
  GALNS                                  Mucopolysaccharidosis IVA                                                                                                                                                                                                        AR
  GLB1                                   Mucopolysaccharidosis IVB                                                                                                                                                                                                        AR
  TNFRSF11B                              Paget disease                                                                                                                                                                                                                    AR
  TNFRSF11A                              Paget disease                                                                                                                                                                                                                    AD
  SQSTM1                                 Paget disease                                                                                                                                                                                                                    AD
  FGFR3                                  Achondroplasia                                                                                                                                                                                                                   AD
  ATP6VOA4                               Renal tubular acidosis with deafness                                                                                                                                                                                             --
  ATP6V1B1                               Renal tubular acidosis with deafness                                                                                                                                                                                             AR
  SLC4A1                                 Renal tubular acidosis with deafness                                                                                                                                                                                             AD/AR
  PHEX                                   Hypophosphatemic rickets, X-linked dominant                                                                                                                                                                                      XLD
  CLCN5                                  Hypophosphatemic rickets, X-linked recessive                                                                                                                                                                                     XLR
  FGF23                                  Hypophosphatemic rickets, autosomal dominant                                                                                                                                                                                     AD
  DMP1                                   Hypophosphatemic rickets, autosomal recessive, 1                                                                                                                                                                                 AR
  ENPP1                                  Hypophosphatemic rickets, autosomal recessive, 2                                                                                                                                                                                 AR
  SLC34A3                                Hypophosphatemic rickets with hypercalciuria                                                                                                                                                                                     AR
  VDR                                    vitamin D-dependent rickets type 2A                                                                                                                                                                                              AR
  CYP27B1                                Vitamin D-dependent rickets type 1A                                                                                                                                                                                              AR
  CYP2R1                                 Vitamin D-dependent rickets type 1B                                                                                                                                                                                              AR
  EHHADH                                 Fanconi renotubular syndrome autosomal dominant FRTS3                                                                                                                                                                            AD
  SLC34A1                                Fanconi renotubular syndrome autosomal recessive FRTS2                                                                                                                                                                           AR
  **GENES RELATED TO PSIS**                                                                                                                                                                                                                                               
  PROP1                                  Pituitary stalk interruption syndrome; Combined pituitary hormone deficiency                                                                                                                                                     AR
  LHX3                                   Pituitary stalk interruption syndrome; Combined pituitary hormone deficiency                                                                                                                                                     AR
  LHX4                                   Pituitary stalk interruption syndrome; Combined pituitary hormone deficiency                                                                                                                                                     AD
  OTX2                                   Pituitary stalk interruption syndrome; Combined pituitary hormone deficiency                                                                                                                                                     AD
  HESX1                                  Pituitary stalk interruption syndrome; Combined pituitary hormone deficiency                                                                                                                                                     AR/AD
  PROKR2                                 Pituitary stalk interruption syndrome; Kallmann syndrome                                                                                                                                                                         AD
  GPR161                                 Pituitary stalk interruption syndrome; Combined pituitary hormone deficiency                                                                                                                                                     --
  CDON                                   Pituitary stalk interruption syndrome; Holoprosencephaly                                                                                                                                                                         AD
  TGIF1                                  Pituitary stalk interruption syndrome; Holoprosencephaly                                                                                                                                                                         AD
  **GENES RELATED TO PHD**                                                                                                                                                                                                                                                
  BTK                                    Agammaglobulinemia and isolated hormone deficiency                                                                                                                                                                               XLR
  POU1F1                                 Combined pituitary hormone deficiency                                                                                                                                                                                            AR/AD
  SOX3                                   Panhypopituitarism X-linked                                                                                                                                                                                                      XL
  FGFR1                                  Hypogonadotropic hypogonadism with or without anosmia                                                                                                                                                                            AD
  FGF8                                   Hypogonadotropic hypogonadism with or without anosmia                                                                                                                                                                            AD
  *CHD7*                                 CHARGE syndrome                                                                                                                                                                                                                  AD
  **GENES RELATED TO HPE**                                                                                                                                                                                                                                                
  SIX3                                   Holoprosencephaly                                                                                                                                                                                                                AD
  SHH                                    Holoprosencephaly                                                                                                                                                                                                                AD
  ZIC2                                   Holoprosencephaly                                                                                                                                                                                                                AD
  PTCH1                                  Holoprosencephaly                                                                                                                                                                                                                AD
  GLI2                                   Holoprosencephaly                                                                                                                                                                                                                AD
  DISP1                                  Holoprosencephaly                                                                                                                                                                                                                --
  FOXH1                                  Holoprosencephaly or cardiac defects                                                                                                                                                                                             --
  NODAL                                  Holoprosencephaly, Heterotaxy,visceral                                                                                                                                                                                           AD
  TDGF1                                  Holoprosencephaly, Forebrain defects                                                                                                                                                                                             --
  GAS1                                   regulator of SHH, Modifier of HPE                                                                                                                                                                                                --
  DLL1                                   Holoprosencephaly                                                                                                                                                                                                                --

*PSIS, Pituitary stalk interruption syndrome; PHD, pituitary hormone deficiency; HPE, holoprosencephaly*.

Therapeutic Intervention and Follow-Up
--------------------------------------

For hypogonadism, 2000 U human chorionic gonadotropin (hCG) was given intramuscularly three times per week, and testosterone and free testosterone levels were re-examined periodically at outpatient visits. The underarm hair and pubic hair of the patient showed significant growth. The testicular volume of the patient increased to 1.47 ml (left) and 1.69 ml (right), and his testosterone levels increased as well but still not reach normal range ([Table 1](#T1){ref-type="table"}). Human menopausal gonadotropin (hMG) was added to the patient\'s medications (75 U along with hCG). For secondary hypothyroidism, levothyroxine administration was started at 25 μg once daily, thyroid function was monitored, and the dose was increased to 75 μg/day during follow-up. For secondary adrenal insufficiency, oral hydrocortisone was prescribed initially at 20 mg in the morning (8:00 a. m.) and 10 mg in the afternoon (3:00 p.m.), and the hydrocortisone dose was decreased to 5 mg/day during follow-up because the body weight of the patient increased quickly and he showed no manifestation of adrenal insufficiency. A dose of 15 mg hydrocortisone was recommended for the patient according to the guideline after carefully discussion with the patient and his family ([@B4]). For OI, bisphosphonates were recommended.

Discussion {#s3}
==========

This paper reports a rare case of OI combined with PSIS; this patient was the index case in one OI family. In this family, the patient, his mother and twin brother presented blue sclera and bone fractures, whereas the father seemed clinically normal. Next-generation sequencing revealed that the twins harbor heterozygous mutations in both *COL1A1* and *COL1A2*. Currently, there are no reports on OI cases with such compound heterozygous mutations involving two genes. The *COL1A1* mutation (p.Arg220Ter) (rs72667036) was inherited from their mother. It causes termination of the α1 chain, thus resulting in a reduced amount of total type I collagen, which has been reported in many papers to result in type 1 OI ([@B5]--[@B9]). The *COL1A2* mutation (p.Pro857Thr) (rs150179964) was inherited from their father. It has an MAF \< 0.01 in the Ensembl database, a SIFT score of 0.02 (deleterious), and a PolyPhen score of 0.036 (benign). A previous paper reported a Vietnamese type IV OI patient carrying p.Pro857Thr associated with a different mutation (p.Gly1012Ser) in *COL1A2* ([@B10]). The *COL1A2* mutation (p.Pro857Thr) was not located at the G (glycine) site of the G-X-X motif, which plays an important role in maintaining the normal protein structure of COL1A1 and COL1A2. Together with a lack of clinical presentation of OI in the patient\'s father, these results suggest that the *COL1A2* mutation (p.Pro857Thr) might have minor effects on the protein structure and function.

Osteogenesis imperfecta is a heterogeneous group of inherited connective tissue disorders that cause bone fragility and deformity ([@B1]). About 90% of OI cases are caused by structural or quantitative mutations in the collagen genes *COL1A1* and *COL1A2* ([@B11], [@B12]). In addition, alterations in more than 13 genes that are linked to collagen processing (*BMP1*), collagen modification (*CRTAP, LEPRE1/P3H1, PPIB, TMEM38B*), collagen folding and cross-linking (*SERPINH1, FKBP10, PLOD2*), bone mineralization (*IFITM5, SERPINF1*), and osteoblast development with collagen insufficiency (*SP7, WNT1, CREB3L1*) have been reported to account for OI. These genetic alterations provide further explanations for the pathogenesis, classification, and therapeutic targets of OI ([@B1]). Osteogenesis imperfecta is a major cause of skeletal deformities and may lead to secondary damages, such as hearing loss ([@B13]), dental abnormalities ([@B14]), neurological features including macrocephaly, hydrocephalus, syringomyelia, and basilar invagination ([@B15]), and short stature with a normal growth axis ([@B16]). Patients with OI may present multiple skeletal deformities, such as flat midface and triangular facies, scoliosis or kyphosis, and chest wall deformities including pectus excavatum, carinatum, and barrel chest ([@B11]).

Interestingly, in the present family, the twins shared the same genetic alterations that accounted for their OI, whereas the index case presented evident delay in growth and development. Obviously, OI was not the reason for these differences between the twins, which were attributed to PSIS. Pituitary stalk interruption syndrome is believed to be associated with genetic and environmental factors, especially perinatal events ([@B3]). More than 40 candidate genes for PSIS, PHD, and HPE have been reported ([@B17]--[@B20]), but only 5% of the PSIS patients were identified to harbor these defects ([@B20], [@B21]). Holoprosencephaly is characterized by severely disturbed midline brain development, and genetic studies have shown an association between PSIS and genes involved in HPE, suggesting that PSIS might be a mild form of HPE ([@B20]). Recent studies have suggested a polygenic etiology for isolated PSIS ([@B19], [@B22], [@B23]). Although there might be additional genetic and epigenetic alterations not yet recognized by the current sequencing technologies, it seems that environmental factors play more important roles in the pathogenesis of PSIS. As shown in previous studies, individuals who had a history of perinatal events, such as breech delivery, were more likely to develop PSIS ([@B24], [@B25]). The frequency of breech delivery among PSIS patients is much higher than that in the general population ([@B26]). The mechanisms behind the higher risk of PSIS caused by perinatal events remain unclear. Pituitary stalk interruption syndrome is reported to be associated with direct injury to the pituitary stalk, or transient anoxia of hypothalamus ([@B3]) during difficult labors. In our case of co-occurrence of OI and PSIS, next-generation sequencing did not show any abnormalities in genes related to PSIS, PHD, or HPE. Considering that the patient was born after a difficult breech delivery, and that his normally delivered twin brother did not present PSIS, we deduced that the PSIS might be a consequence of breech delivery. Studies assessing at-birth health outcomes of neonates with OI reported a high breech delivery rate (24--37%), suggesting that newborns with OI may benefit from additional clinical supervision ([@B27], [@B28]). However, we still cannot exclude the possibility that the proband may have an undetected genetic abnormality causing PSIS or increasing his susceptibility to damage to the hypothalamic-pituitary region, owing to the limitations of exome sequencing.

To the best of our knowledge, the available case reports on PSIS have never mentioned its co-occurrence with OI. The present report reminds us to further investigate the influence of OI in female patients on vaginal deliveries, perinatal events, and the incidence of PSIS among their offspring. If female OI patients unfortunately experience perinatal events, their offspring should be monitored for early identification of any pituitary dysfunction, which may lead to development and growth delay.
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